1033224-84-8

Basic information

• Product Name: 1-(2-Methylphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide
• Synonyms: 1-(2-Methylphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide
• CAS NO: 1033224-84-8
• Molecular Formula: C₁₃H₁₂N₂O₂S
• Molecular Weight: 260.31158
• Mol File: 1033224-84-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-Methylphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Methylphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide(1033224-84-8)
• EPA Substance Registry System: 1-(2-Methylphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide(1033224-84-8)

Safety Data

• Hazardous Substances Data: 1033224-84-8(Hazardous Substances Data)

Usage

General Description

1-(2-Methylphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide, also known as Methyldopa, is a synthetic chemical compound used as an antihypertensive medication. It works by inhibiting the synthesis of neurotransmitters like norepinephrine, and has been shown to be effective in treating high blood pressure. Methyldopa is also used in the treatment of preeclampsia during pregnancy. The chemical structure of Methyldopa includes a benzene ring with a methyl group and a benzothiadiazole moiety, with oxygen atoms connected to the benzene and benzothiadiazole ring. Overall, Methyldopa is an important pharmaceutical agent that plays a critical role in the management of hypertension.

Upstream product

• 68874-23-7 N-o-tolyl-o-phenylenediamine 

Relevant articles and documents

Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3 H)-yl]-1-(methylamino)butan-2- ols (WYE-103231)

Structural modification of a virtual screening hit led to the identification of a new series of 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol- 1(3H)-yl]-1-(methylamino)butan-2-ols which are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and dopamine transporters. One representative compound S-17b (WYE-103231) had low nanomolar hNET potency (IC50 = 1.2 nM) and excellent selectivity for hNET over hSERT (>1600-fold) and hDAT (>600-fold). S-17b additionally had a good pharmacokinetic profile and demonstrated oral efficacy in rat models of ovariectomized-induced thermoregulatory dysfunction and morphine dependent flush as well as the hot plate and spinal nerve ligation (SNL) models of acute and neuropathic pain.